PRESS RELEASE published on 03/25/2024 at 07:10, 2 years 3 months ago Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform Financial Results Business Performance HDP-101 ADC Technology Heidelberg Pharma AG
BRIEF published on 03/19/2024 at 09:52, 2 years 3 months ago Heidelberg Pharma Receives Upfront Payment from HealthCare Royalty Agreement Heidelberg Pharma HealthCare Royalty Zircaix Antibody Drug Conjugates Biotech Funding
BRIEF published on 03/19/2024 at 09:52, 2 years 3 months ago Heidelberg Pharma reçoit un paiement initial dans le cadre d'un accord de redevances sur les soins de santé Conjugués Anticorps-médicament Heidelberg Pharma Zircaix Redevance En Matière De Soins De Santé Financement Biotechnologique
PRESS RELEASE published on 03/19/2024 at 09:47, 2 years 3 months ago Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway Heidelberg Pharma HealthCare Royalty ADC Pipeline Royalty Purchase Agreement Cash Payment
BRIEF published on 03/18/2024 at 07:30, 2 years 3 months ago Heidelberg Pharma Advances to Cohort 6 in Multiple Myeloma Study with HDP-101 Heidelberg Pharma HDP-101 Multiple Myeloma Phase I/IIa Study Cohort 6
BRIEF published on 03/18/2024 at 07:30, 2 years 3 months ago Heidelberg Pharma passe à la cohorte 6 dans l'étude sur le myélome multiple avec HDP-101 Heidelberg Pharma HDP-101 Myélome Multiple Étude De Phase I/IIa Cohorte 6
PRESS RELEASE published on 03/18/2024 at 07:25, 2 years 3 months ago Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study Heidelberg Pharma progresses into Cohort 6 with ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study, showing first objective responses and partial remissions. Amended protocol includes optimized dosing regimens Heidelberg Pharma Multiple Myeloma Phase I/IIa Study ATAC Candidate Protocol Amendment
PRESS RELEASE published on 03/07/2024 at 12:27, 2 years 4 months ago Original-Research: Heidelberg Pharma AG (von EQUITS GmbH): Kaufen EQUI.TS GmbH bekräftigt Anlageurteil KAUFEN für Heidelberg Pharma AG nach Royalty-Verkauf an HCRx, der die F&E Aktivitäten beschleunigt und das ZircaixTM Potential um 50% steigert Heidelberg Pharma AG EQUI.TS GmbH Royalty-Verkauf ZircaixTM Potential F&E Aktivitäten
BRIEF published on 03/06/2024 at 07:51, 2 years 4 months ago Heidelberg Pharma to Showcase HDP-101 Efficacy and ADC Technology at AACR 2024 Cancer Research Heidelberg Pharma HDP-101 ADC Technology AACR Meeting 2024
BRIEF published on 03/06/2024 at 07:51, 2 years 4 months ago Heidelberg Pharma présentera l'efficacité du HDP-101 et la technologie ADC à l'AACR 2024 Recherche Contre Le Cancer Heidelberg Pharma HDP-101 Technologie CAN Réunion AACR 2024
Published on 07/14/2026 at 01:45, 5 hours 32 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 7 hours 16 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 8 hours 7 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 9 hours 42 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 11 hours 17 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/14/2026 at 07:00, 17 minutes ago The Swiss are confident about the future despite acknowledging some areas of concern
Published on 07/14/2026 at 07:00, 17 minutes ago Malgré quelques inquiétudes, la Suisse envisage l’avenir avec confiance
Published on 07/14/2026 at 06:30, 47 minutes ago Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars
Published on 07/14/2026 at 04:45, 2 hours 32 minutes ago Asia’s Debut of LEAP East in HKCEC Marks Hong Kong’s Largest Inaugural Tech Summit
Published on 07/13/2026 at 18:00, 13 hours 17 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 13 hours 17 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 13 hours 17 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026